Skip to main content
Equibles
TWST logo

TWST · Twist Bioscience Corp · Metrics

Track TWST — free

Use TWST with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TWST.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$143.85 +4.08 (+2.92%)
Russell 2000 member Rebalance outlook locked
Market Cap
$8.53B
Shares
62.71M
Volume · Oct 20 2.01M Avg daily vol (3M) 2.18M

TWST metrics

90 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$142.70
Market cap
$8.53B

Price action

20 metrics
Price change (1W)
-8.0%
Price change (30D)
-15.7%
Price change (3M)
+59.8%
Price change (6M)
+125.9%
Price change (YTD)
+340.6%
Price change (1Y)
+396.3%
Trailing year
Price change (5Y)
+16.6%
52-week high
$205.00
52-week low
$25.45
Change from 52-week high
-31.8%
Change from 52-week low
+449.2%
Annualized volatility
78.2%
Annualized volatility (3M)
102.0%
Beta
2.7
RSI (14D)
42.3
Price vs SMA 50
-5.8%
Price vs SMA 200
+66.8%
Avg volume (3M)
2.16M
Relative volume
0.7
Average dollar volume
$314.57M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
62.71M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
18.9×
reciprocal yield 5.3%
EV / EBITDA
—
EV / EBIT
—
P / sales
19.3×
reciprocal yield 5.2%
P / book
18.7
reciprocal yield 5.4%
FCF yield
-1.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
6.7×
reciprocal yield 14.9%
EV / revenue historical average (5Y)
10.2×
reciprocal yield 9.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-03

Profitability

9 metrics
Gross margin
52.0%
Operating margin
-33.6%
Trailing 12 months
Net margin
-31.7%
Gross profit (TTM)
$224.38M
Operating profit (TTM)
−$144.98M
Net income (TTM)
−$136.72M
Trailing 12 months
Diluted EPS (TTM)
$-2.21
FCF margin
-21.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$7.06
Gross profit per diluted share (TTM)
$3.67
Operating profit per diluted share (TTM)
$-2.37
EBITDA per diluted share (TTM)
$-1.95
Net income per diluted share (TTM)
$-2.23
Operating cash flow per diluted share (TTM)
$-0.87
Free cash flow per diluted share (TTM)
$-1.53
Capital expenditures per diluted share (TTM)
$0.66
R&D per diluted share (TTM)
$1.18
Stock compensation per diluted share (TTM)
$1.09
Book value per share
$7.80

Growth

11 metrics
Revenue growth YoY
+23.2%
Year over year
Net income growth YoY
-271.9%
Revenue (TTM)
$431.80M
Trailing 12 months
EPS growth YoY
-269.7%
Shares change YoY
+2.0%
Year over year · more shares
Revenue CAGR (3Y)
+22.8%
Revenue CAGR (5Y)
+33.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-30.7%
Return on assets
-20.3%
Debt / equity
0.0
Current ratio
2.7
EBITDA (TTM)
−$119.59M
Free cash flow (TTM)
−$93.12M
Quick ratio
2.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$151.84M
Latest balance sheet
Cash & equivalents
$117.44M
Total assets
$672.44M
Total debt
$15.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$53.07M
Capital expenditures (TTM)
$40.05M
R&D (TTM)
$71.86M
SG&A (TTM)
$290.29M
Stock compensation (TTM)
$66.47M
R&D / revenue
16.6%
Stock compensation / revenue
15.4%

Ownership (13F)

9 metrics
13F filers
339
13F filer change QoQ
+57
Institutional ownership
122.7%
Conviction holders (share of 13F filers)
2.1%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-0.5%
Holder tenure
15.8
Price vs estimated holder cost
+123.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
20.8%

Short interest

3 metrics
Short interest
16.9%
Latest settlement · 3.8 days to cover
Days to cover
3.8d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$119.96M
Insider-sentiment score
7 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1581280 CUSIP 90184D100 13F (30d) 30 filings 30 filers Visit website Investor relations